The number of therapeutic options for the treatment of moderate to severe psoriatic disease have increased exponentially over the past decade. Immunomodulating therapies can help a majority of patients receiving the therapy achieve and maintain Psoriasis Area and Severity Index 100 scores for short- and long-term periods of time.
How have newer biologics impacted your practice? Let us know below!
Leading dermatologic therapy researcher Andrew Blauvelt, MD, MBA, details the differences in maintenance of response and safety of various biologic therapies for the treatment of plaque psoriasis. Watch his 5-minute interview